Followers | 4053 |
Posts | 151263 |
Boards Moderated | 4 |
Alias Born | 08/05/2009 |
Wednesday, December 01, 2021 8:29:42 AM
Recent lung cancer data was a little disappointing, but investors may be missing the point here. Plinabulin isn't intended to fight cancer directly. It's meant to stop toxic chemotherapy from destroying white blood cells. A lack of white blood cells, or neutropenia, is a dangerous complication that frequently interrupts chemotherapy treatment.
On or before Nov. 30, 2021, the FDA is expected to issue an approval decision for BeyondSpring's lead candidate plinabulin. If given a green light to treat chemotherapy-induced neutropenia, it could become an important new treatment for lots of different cancer patients.
Message in reply to:
BeyondSpring To Present Final Phase 3 DUBLIN-3 Data With Plinabulin/Docetaxel Combination Versus Docetaxel Alone In 2nd/3rd Line Non-Small Cell Lung Cancer Patients With EGFR Wild Type At European Society for Medical Oncology 2021 Congress Sept. 16-21
Recent BYSI News
- BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics • GlobeNewswire Inc. • 05/03/2024 11:00:00 AM
- BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results • GlobeNewswire Inc. • 04/29/2024 09:30:00 PM
- BeyondSpring Files 2023 Annual Report on Form 20-F • GlobeNewswire Inc. • 04/29/2024 09:30:00 PM
- BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer • GlobeNewswire Inc. • 03/25/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/26/2024 01:01:19 PM
- BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:30:59 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/02/2024 09:30:32 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/16/2024 09:30:13 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/10/2024 08:00:38 PM
- BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K • GlobeNewswire Inc. • 01/10/2024 08:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/18/2023 09:31:23 PM
- BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements • GlobeNewswire Inc. • 12/18/2023 09:30:00 PM
- BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors • GlobeNewswire Inc. • 11/07/2023 12:00:00 PM
- BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models • GlobeNewswire Inc. • 10/31/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/30/2023 12:05:19 PM
- BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 10/30/2023 12:00:00 PM
- SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium • GlobeNewswire Inc. • 10/26/2023 12:30:00 PM
- SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors • GlobeNewswire Inc. • 10/23/2023 11:45:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/04/2023 08:00:38 PM
- BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements • GlobeNewswire Inc. • 10/04/2023 07:55:00 PM
- BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting • GlobeNewswire Inc. • 09/27/2023 02:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/20/2023 09:20:19 PM
- BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference • GlobeNewswire Inc. • 09/07/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/14/2023 08:30:54 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM